Shanghai Shyndec Pharmaceutical

Shanghai Shyndec Pharmaceutical

Shanghai Shyndec Pharmaceutical was established in 1996, sponsored by the Shanghai Institute of Pharmaceutical Industry (SIPI) and now held as a 41.62% stake by China National Pharmaceutical Group (Sinopharm). Shanghai Pharmaceuticals Holding holds an additional 25.67% interest, anchoring Shyndec within two of China's largest state-linked pharmaceutical networks. Shyndec's product portfolio covers systemic anti-infectives, cardiovascular and cerebrovascular agents, nervous-system drugs, oncology and immunomodulators, systemic hormone preparations, and musculoskeletal therapies. Its reach extends across China through a network of over 20 production bases, including a dedicated facility in Haimen, Jiangsu Province. The firm participates in the Sinopharm Industrial Investment joint venture alongside Fosun Pharmaceutical, blending a corporate balance-sheet approach with co-investor capital deployment in the pharmaceutical and healthcare sectors. Headquartered at No. 378 Jianlu Road in Pudong, Shanghai, with a commercial office in Sinopharm Plaza in Beijing's Haidian District, Shyndec maintains memberships in the China Pharmaceutical Industry Association, the China National Narcotic Drugs Association and the China Association of Pharmaceutical Commerce. The firm's drug approvals portfolio spans multiple therapeutic categories, and its manufacturing infrastructure positions it as a production-oriented entity within the Sinopharm group. Shyndec's architecture as a publicly listed pharmaceutical manufacturer with a state-owned parent creates a distinct governance layer: strategic direction flows from Sinopharm, but the Shanghai listing imposes public-market disclosure and minority-shareholder disciplines. The SIPI research lineage — the institute that originally founded the company — provides a link to China's state pharmaceutical R&D ecosystem that most pure-play manufacturers lack.